graph Evidence gap map comparisons
atezolizumab based treatmentpembrolizumab based treatment
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel atezolizumab plus carboplatin plus nab-paclitaxel atezolizumab plus carboplatin plus paclitaxel atezolizumab plus pemetrexed and platin pembrolizumab and pemetrexed plus platin pembrolizumab plus SoC
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population 3       
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT) 6            
Comparator:  vs bevacizumab plus carboplatin and paclitaxel;   vs atezolizumab plus carboplatin plus nab-paclitaxel;   vs carboplatin plus nab-paclitaxel;   vs pemetrexed plus platin;   vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;